292 related articles for article (PubMed ID: 31328653)
21. PD-L1 expression in tongue squamous cell carcinoma.
Akisada N; Nishimoto K; Takao S; Gion Y; Marunaka H; Tachibana T; Makino T; Miki K; Akagi Y; Tsumura M; Toji T; Yoshino T; Nishizaki K; Orita Y; Sato Y
Med Mol Morphol; 2021 Mar; 54(1):52-59. PubMed ID: 32699939
[TBL] [Abstract][Full Text] [Related]
22. Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?
Fonseca L; Freitas C; Caramelo A; Eloy C
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00241. PubMed ID: 34277966
[TBL] [Abstract][Full Text] [Related]
23. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors that influence the course of medullary thyroid carcinoma.
Pazaitou-Panayiotou K; Chrisoulidou A; Mandanas S; Tziomalos K; Doumala E; Patakiouta F
Int J Clin Oncol; 2014; 19(3):445-51. PubMed ID: 23832286
[TBL] [Abstract][Full Text] [Related]
25. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
26. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
He J; Chen XF; Xu MG; Zhao J
Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
28. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 expression in nonclear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gray KP; Callea M; Ho TH; Albiges L; Bellmunt J; Song J; Carvo I; Lampron M; Stanton ML; Hodi FS; McDermott DF; Atkins MB; Freeman GJ; Hirsch MS; Signoretti S
Ann Oncol; 2014 Nov; 25(11):2178-2184. PubMed ID: 25193987
[TBL] [Abstract][Full Text] [Related]
31. Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
Shim KH; Kwon JE; Park SG; Choo SH; Kim SJ; Kim SI
Urol Oncol; 2021 May; 39(5):298.e13-298.e20. PubMed ID: 33712343
[TBL] [Abstract][Full Text] [Related]
32. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
[TBL] [Abstract][Full Text] [Related]
36. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
37. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
39. Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan.
Ito Y; Miyauchi A; Kihara M; Higashiiyama T; Fukushima M; Miya A
World J Surg; 2018 Dec; 42(12):3954-3966. PubMed ID: 30051240
[TBL] [Abstract][Full Text] [Related]
40. Prediction of biochemical cure in patients with medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
Br J Surg; 2020 May; 107(6):695-704. PubMed ID: 32108330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
